

Key Investor Information

This document provides you with key investor information about this Fund. It is not marketing material. The information is required by law to help you understand the nature and the risks of investing in this Fund. You are advised to read it so you can make an informed decision about whether to invest.

Atlantis China Healthcare Fund: US Dollar Units
A sub-fund of the Atlantis International Umbrella Fund

ISIN: IE00B1WL3F32

Managed by Atlantis Investment Management (Ireland) Limited.

Objectives and Investment Policy

The fund aims to generate long-term capital appreciation.

The fund invests primarily in securities issued by companies listed in Hong Kong, the People's Republic of China, Singapore, the United States or the United Kingdom which are principally engaged in health related industries in China, including pharmaceuticals, bio-technology, medical devices, healthcare providers, hospitals, nursing homes and environmental protection. Such securities will include equity securities, equity-related securities, American Depositary Receipts, Global Depositary Receipts, debt securities (such as debentures, fixed or floating rate corporate or sovereign notes and bonds) of investment grade or below investment grade and money market instruments (such as treasury bills, certificates of deposit, commercial paper and bankers acceptances). The fund will not invest in other open-ended collective investment schemes and will at all times invest more than 50% of its net asset value directly in equity securities. Subject to the equity securities quota, the fund may also invest in cash and in real estate investment trusts (REITs) which are listed on the Shanghai Stock Exchange, the Shenzhen Stock Exchange, the Singapore Stock Exchange or on the Hong Kong Stock Exchange provided that they do not affect the ability of the fund to meet its liquidity obligations. The fund may invest indirectly in the A-share market by purchasing equity linked securities which will constitute transferable securities which will be listed, traded or dealt on a recognised exchange or, unlisted securities. In the case of unlisted securities, such investment shall not exceed 10% of the fund's net asset value. The fund may invest in have direct access to A-shares listed on the Shanghai Stock Exchange via the Shanghai-Hong

Kong Stock Connect scheme and/or the Shenzhen Stock Exchange via the Shenzhen- Hong Kong Stock Connect scheme. Exposure to A-shares through the Connect Schemes will not be more than 50% of the fund's net asset value.

The fund is considered to be actively managed in reference to the Hang Seng Healthcare Index (the "Benchmark") by virtue of the fact that it uses the Benchmark for performance comparison purposes. Certain of the fund's securities may be components of and may have similar weightings to the Benchmark. However the Benchmark is not used to define the portfolio composition of the fund or as a performance target and the Fund may be wholly invested in securities which are not constituents of the Benchmark.

Any income arising from the fund's investments is reinvested.

Units can normally be bought on any business day, being a day on which banks are open for business in Dublin, London, Shanghai and Hong Kong.

Units can normally be sold twice per month, on the 1st and 15th calendar days of each calendar month or if such a day is not a business day being a day on which banks are open for business in Dublin, London, Shanghai and Hong Kong, then the next subsequent business day shall be a redemption day.

For further information please see the 'Investment Objective and Policies' section of the supplement to the prospectus for the fund.

Risk and Reward Profile

Lower risk ← Higher risk
Potentially lower reward ← Potentially higher reward



- Historical data may not be a reliable indication for the future.
- The risk category shown is not guaranteed and may shift over time.
- The lowest category does not mean 'risk free'.

Why is the fund in this category?

Funds in this category have shown a high historical volatility. Volatility describes how much the value of the fund went up and down in the past.

The smaller size and lower trading volumes of the markets for Chinese securities may result in a potential lack of liquidity and increased volatility as compared to more developed securities markets.

The value of the fund's investments may be affected by political and regulatory uncertainties in China. Chinese fiscal, monetary, legal, accounting and stock market systems are underdeveloped relative to Western countries.

The fund invests in the shares of smaller to medium sized companies which may have a more limited market than securities issued by larger companies.

The fund mainly invests in one sector within one country. It is therefore vulnerable to the market sentiment of that sector and country. This type of fund can carry a higher risk when compared to a fund with a broader investment universe.

This unit class's net asset value is calculated in US dollars while the fund's investments are denominated in the currencies of the countries in which it invests. The fund's performance may therefore be adversely affected by exchange rate movements.

For further information please see the 'Risk Factors' section of the supplement to the prospectus for the fund.

Charges

The charges you pay are used to pay the costs of running the Fund, including the costs of marketing and distributing it. These charges reduce the potential growth of your investment.

One-off charges taken before or after you invest	
Entry charge	No charge
Exit charge	No charge
Charges taken from the Fund over a year	
Ongoing charges	1.56 %
Charges taken from the Fund under certain specific conditions	
Performance fee	20.00 % of those gains achieved above a 5.00% annual increase in the value of the fund subject to a high water mark.


The ongoing charge is based on the fund's total expenses for the last financial year ending 31 December 2021. This figure may vary from year to year. It excludes:

- performance fees; and
- portfolio transaction costs, except in the case of an entry/exit charge paid by the fund when buying or selling units in another collective investment undertaking.

The performance fee paid for the fund's last financial year was 0%.

For more information about charges, including performance fees, please see the "Fees" section of the supplement to the prospectus for the fund.

Past Performance



- Past performance is not a reliable indicator of future performance.
- The past performance shown is calculated in US dollars.
- The fund was launched in 2007. This unit class was launched in 2007.
- The performance of the unit class is not tracking the indices in the chart.
- Comparisons were made with respect to MSCI China All Shares Health Care 10/40/ Net Return USD Index from 2013 to 2020.

Practical Information

- Only one unit class of the fund has been described here. Further information on all unit classes is available in the prospectus.
- Depositary: Northern Trust Fiduciary Services (Ireland) Limited.
- The fund is subject to the tax laws of Ireland. This may affect your personal tax position. For further information, please speak to your personal tax adviser.
- Atlantis Investment Management (Ireland) Limited may be held liable solely on the basis of any statement contained in this document that is misleading, inaccurate or inconsistent with the relevant parts of the prospectus for the fund.
- The fund is a sub-fund of the Atlantis International Umbrella Fund (the "Trust"). You may switch into units of a different sub-fund of the Trust. Details on switching rules can be found in the prospectus. The assets of each sub-fund are segregated from other sub-funds of the Trust. This key investor information document describes a single fund. The prospectus and periodic reports are prepared for the entire Trust.
- Details of the Manager's up-to-date remuneration policy, including, but not limited to, a description of how remuneration and benefits are calculated, the identity of persons responsible for awarding the remuneration and benefits, is available at www.atlantis-investment.com and a paper copy of such remuneration policy is available to investors free of charge upon request.
- Further information in English about the Trust, including the latest unit prices, the prospectus and the yearly and half-yearly report and accounts, may be obtained free of charge from Atlantis Investment Management (Ireland) Limited, George's Court, 54-62 Townsend Street, Dublin 2, Ireland (email: investment@atlantis-investment.com) or, in the UK from Global Funds Registration Ltd, 2nd Floor, Golden House, 30 Great Pulteney Street, London W1F 9NN, Tel: +44(0) 207 532 4208. This information is also available in such other languages as disclosed on www.atlantis-investment.com.
- The prospectus, the key investor information documents, the trust deed as well as the annual and semi annual reports can be obtained free of charge from the representative in Switzerland, Oligo Swiss Fund Services SA, Avenue Villamont 17, 1005 Lausanne, Switzerland. The paying agent in Switzerland is Helvetische Bank, Seefeldstrasse 215, CH-8008 Zurich.

This Fund is authorised in Ireland and regulated by the Central Bank of Ireland.

This Key Investor Information is accurate as at 09 February 2022.